Text Size

Effect of Turmeric on Diabetic Nephropathy

This study has been completed.
Sponsor:
Collaborator:
Shiraz University of Medical Sciences
Information provided by:
Shaheed Faghihi Hospital
ClinicalTrials.gov Identifier:
NCT01015937
First received: November 16, 2009
Last updated: November 17, 2009
Last verified: November 2009
History of Changes
  Purpose

The purpose of this study is to investigate whether turmeric is effective in improvement of diabetic nephropathy and in decrease in the amount of proteinuria and cytokine levels.


Condition Intervention
Diabetic Nephropathy
Proteinuria
 Drug: Turmeric extract
Drug: Angiotensin-converting enzyme (ACE) inhibitor + Angiotensin-II type 1 receptor (ATI) blocker

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Shaheed Faghihi Hospital:

Enrollment: 50
Study Start Date: March 2008
Study Completion Date: August 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Turmeric

diabetic nephropathy patient

more than 300 mg/proteinuria

 Drug: Turmeric extract
turmeric 500 mg TID for 45 days
Other Name: turmeric
Active Comparator: ACE inhibitor + ATI blocker

diabetic nephropathy

more than 300 mg/day proteinuria

 Drug: Turmeric extract
turmeric 500 mg TID for 45 days
Other Name: turmeric
Drug: Angiotensin-converting enzyme (ACE) inhibitor + Angiotensin-II type 1 receptor (ATI) blocker
maximum dosage as patient tolerated for 45 days
Other Names:
  • enalapril
  • losartan

Detailed Description:

Diabetic nephropathy is leading cause of ESRF that many therapy recommended for it. In this study, we investigate effect of turmeric on diabetic nephropathy, thus we selected diabetic nephropathy patients and divided them into 2 groups. One group received turmeric + ACE inhibitor + Angiotensin II receptor blocker (ARB) and the second group received only ACE inhibitor + ARB.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • diabetic nephropathy
  • more than 300 mg proteinuria/day
  • age more than 18 years old

Exclusion Criteria:

  • DM type 1
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01015937

Locations
Iran, Islamic Republic of
Clinic
Shiraz, Fars, Iran, Islamic Republic of, 098
Sponsors and Collaborators
Shaheed Faghihi Hospital
Shiraz University of Medical Sciences
Investigators
Principal Investigator: maryam pakfetrat, assistant professor Shiraz nephro-urology research center
  More Information

Additional Information:
Related Info  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Office of Vice Chancellor for research in Shiraz UMS, Shiraz University of Medical Science
ClinicalTrials.gov Identifier: NCT01015937     History of Changes
Other Study ID Numbers: 3997
Study First Received: November 16, 2009
Last Updated: November 17, 2009
Health Authority: Iran: Ministry of Health

Keywords provided by Shaheed Faghihi Hospital:
diabetes
nephropathy
turmeric
serum IL8
 serum TGFb
serumINF
urinary IL8
urine TGFb

Additional relevant MeSH terms:
Diabetic Nephropathies
Kidney Diseases
Proteinuria
Urologic Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Urination Disorders
Urological Manifestations
Signs and Symptoms
Angiotensin II
Angiotensin-Converting Enzyme Inhibitors
 Turmeric extract
Vasoconstrictor Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antioxidants
Protective Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 16, 2013